Glimikem-Mp1 Tablet (Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg)

Composition (per tablet):

Glimepiride 1 mg,Pioglitazone 15 mg,Metformin Hydrochloride 500 mg
Manufacturer: Alkem Laboratories Ltd.

Description:

Glimikem-MP1 Tablet is a triple-combination oral antidiabetic medication used in the treatment of Type 2 Diabetes Mellitus (T2DM).
It combines Glimepiride (sulfonylurea), Pioglitazone (thiazolidinedione), and Metformin (biguanide) — each addressing different aspects of blood glucose regulation to achieve optimal glycemic control.

Warnings & Precautions:

Monitor blood glucose and HbA1c regularly.

Periodic liver and kidney function tests advised.

Use with caution in elderly, cardiac, or edematous patients.

Avoid alcohol (risk of lactic acidosis from Metformin).

May cause weight gain or fluid retention (due to Pioglitazone).

Adverse Effects:

Common: Hypoglycemia, nausea, abdominal discomfort, dizziness, headache, edema, weight gain.

Less common: Lactic acidosis, hepatic dysfunction, visual disturbances, anemia.

Storage:

Store below 25°C, in a dry place, protected from light and moisture.
Keep out of reach of children.